HomeProductsBioactive CompoundsImmunology & InflammationNLRDapansutrile
Chemical structure of CAS 54863-37-5

Dapansutrile

CAS No.54863-37-5
MDL No.MFCD11934305
MFC4H7NO2S
MW133.17
InChI KeyLQFRYKBDZNPJSW-UHFFFAOYSA-N

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
- -On RequestOn Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.54863-37-5
Product NameDapansutrile

Biological Targets

NLRP3

Associated Conditions

COVID-19·melanoma·type 2 diabetes mellitus·Schnitzler syndrome·myocardial infarction·
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

Pharmacologic inhibition of NLRP3 reduces the levels of α-synuclein and protects dopaminergic neurons in a model of Parkinson's disease.

Journal of neuroinflammation • Vol. 20, Issue 1 • 2023
PMID: 37349821PMC: PMC10286423DOI: 10.1186/s12974-023-02830-w

Dapansutrile ameliorated chondrocyte inflammation and osteoarthritis through suppression of MAPK signaling pathway.

Human & experimental toxicology • Vol. 41 • 2022
PMID: 36508695DOI: 10.1177/09603271221145401

Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trial.

The Lancet. Rheumatology • Vol. 2, Issue 5 • 2020
PMID: 33005902PMC: PMC7523621DOI: 10.1016/s2665-9913(20)30065-5

The IUPHAR Guide to Immunopharmacology: connecting immunology and pharmacology.

Immunology • Vol. 160, Issue 1 • 2020
PMID: 32020584PMC: PMC7160657DOI: 10.1111/imm.13175

Documentation